Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.8% – Here’s Why

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s share price fell 2.8% during trading on Wednesday . The company traded as low as $7.37 and last traded at $7.56. 29,568 shares traded hands during trading, a decline of 55% from the average session volume of 65,741 shares. The stock had previously closed at $7.78.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARMP. Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research note on Monday, May 18th. HC Wainwright increased their price objective on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Stock Performance

The stock’s fifty day moving average price is $9.75 and its 200-day moving average price is $8.40. The company has a market capitalization of $277.53 million, a P/E ratio of -0.97 and a beta of 1.21.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million. On average, research analysts predict that Armata Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Armata Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in shares of Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after purchasing an additional 8,198 shares during the period. Jane Street Group LLC bought a new position in Armata Pharmaceuticals in the 4th quarter valued at about $108,000. Millennium Management LLC bought a new position in Armata Pharmaceuticals in the 4th quarter valued at about $164,000. OMERS ADMINISTRATION Corp bought a new position in Armata Pharmaceuticals in the 4th quarter valued at about $177,000. Finally, SeaCrest Wealth Management LLC raised its holdings in Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the period. 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.